Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3-4
|
pubmed:dateCreated |
1991-5-14
|
pubmed:abstractText |
Cultures of human rheumatoid synovial cells and rabbit articular chondrocytes were exposed to various concentrations of Etodolac (from 0.01 to 10 micrograms/ml) in presence or absence of 500 pg/ml (5 U/ml) human recombinant Interleukin-1 beta (IL-1 beta). Incubation of chondrocytes with Etodolac for 24 h did not alter collagen biosynthesis. In contrast, 1 micrograms/ml Etodolac caused a 20% increase of collagen production in synoviocytes. Addition of Etodolac in combination with IL-1 could partially suppress the inhibitory effect exerted by the cytokine on both cell types. Four-day exposure of chondrocytes to 0.1 and 1 micrograms/ml Etodolac led to an increased accumulation of collagen in the cell layer compartment. However, this treatment could not prevent the inhibitory effect of IL-1 on this collagen fraction. Treatment of synoviocytes for eight days with the same concentrations of Etodolac did not modify their collagen production but suppressed totally the inhibitory effect of IL-1. These data show that Etodolac is able to augment chondrocyte metabolism during a long term treatment. Moreover, under certain conditions, this drug can reduce or even suppress the IL-1-induced inhibition of collagen biosynthesis, a process that may take a part in the connective tissue alterations associated with osteoarticular diseases such as rheumatoid arthritis and osteoarthritis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Etodolac,
http://linkedlifedata.com/resource/pubmed/chemical/Indoleacetic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0065-4299
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
345-52
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2150740-Animals,
pubmed-meshheading:2150740-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:2150740-Cartilage, Articular,
pubmed-meshheading:2150740-Cells, Cultured,
pubmed-meshheading:2150740-Collagen,
pubmed-meshheading:2150740-Etodolac,
pubmed-meshheading:2150740-Extracellular Matrix,
pubmed-meshheading:2150740-Humans,
pubmed-meshheading:2150740-Indoleacetic Acids,
pubmed-meshheading:2150740-Interleukin-1,
pubmed-meshheading:2150740-Rabbits,
pubmed-meshheading:2150740-Rheumatic Diseases,
pubmed-meshheading:2150740-Synovial Membrane
|
pubmed:year |
1990
|
pubmed:articleTitle |
Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. I: Collagen synthesis.
|
pubmed:affiliation |
Laboratoire de Biochimie du Tissu Conjonctif, C.H.U. Côte de Nacre, Caen, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|